223 related articles for article (PubMed ID: 24766542)
1. Agomelatine in treating generalized anxiety disorder.
Demyttenaere K
Expert Opin Investig Drugs; 2014 Jun; 23(6):857-64. PubMed ID: 24766542
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine for the treatment of generalized anxiety disorder.
Buoli M; Grassi S; Serati M; Altamura AC
Expert Opin Pharmacother; 2017 Sep; 18(13):1373-1379. PubMed ID: 28730851
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data.
De Berardis D; Conti CM; Marini S; Ferri F; Iasevoli F; Valchera A; Fornaro M; Cavuto M; Srinivasan V; Perna G; Carano A; Piersanti M; Martinotti G; Di Giannantonio M
Int J Immunopathol Pharmacol; 2013; 26(2):299-304. PubMed ID: 23755745
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Stein DJ; Ahokas AA; de Bodinat C
J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Millan MJ
Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
[TBL] [Abstract][Full Text] [Related]
6. [Agomelatine].
Tessmer M
Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
8. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
[TBL] [Abstract][Full Text] [Related]
10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine for the treatment of major depressive disorder.
Carney RM; Shelton RC
Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
[TBL] [Abstract][Full Text] [Related]
14. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.
Stein DJ
Adv Ther; 2021 Sep; 38(Suppl 2):52-60. PubMed ID: 34417992
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
17. A benefit-risk assessment of agomelatine in the treatment of major depression.
Howland RH
Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
Kennedy SH; Rizvi SJ
CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
[TBL] [Abstract][Full Text] [Related]
19. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
20. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
